NCT03020134View on ClinicalTrials.gov

Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 15, 2016

Primary Completion Date

August 22, 2016

Study Completion Date

August 22, 2016

Conditions
Healthy
Interventions
DRUG

Ravidasvir

Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23

DRUG

Danoprevir

Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23

DRUG

Ritonavir

Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23

DRUG

Placebo

Placebo

Sponsors
All Listed Sponsors
lead

Ascletis Pharmaceuticals Co., Ltd.

INDUSTRY